- Home
- THFF vs PHAR Comparison
THFF vs PHAR Comparison
Compare THFF & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THFF
- PHAR
- Stock Information
- Founded
- THFF 1984
- PHAR 1988
- Country
- THFF United States
- PHAR Netherlands
- Employees
- THFF N/A
- PHAR N/A
- Industry
- THFF Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- THFF Finance
- PHAR Health Care
- Exchange
- THFF Nasdaq
- PHAR Nasdaq
- Market Cap
- THFF 625.8M
- PHAR 718.1M
- IPO Year
- THFF N/A
- PHAR N/A
- Fundamental
- Price
- THFF $54.19
- PHAR $11.00
- Analyst Decision
- THFF Buy
- PHAR Strong Buy
- Analyst Count
- THFF 2
- PHAR 3
- Target Price
- THFF $56.50
- PHAR $30.00
- AVG Volume (30 Days)
- THFF 54.1K
- PHAR 3.0K
- Earning Date
- THFF 07-22-2025
- PHAR 07-31-2025
- Dividend Yield
- THFF 3.75%
- PHAR N/A
- EPS Growth
- THFF N/A
- PHAR N/A
- EPS
- THFF 4.63
- PHAR N/A
- Revenue
- THFF $215,577,000.00
- PHAR $320,708,000.00
- Revenue This Year
- THFF $29.97
- PHAR $13.31
- Revenue Next Year
- THFF $2.84
- PHAR $7.68
- P/E Ratio
- THFF $11.75
- PHAR N/A
- Revenue Growth
- THFF 9.26
- PHAR 24.13
- 52 Week Low
- THFF $35.62
- PHAR $6.65
- 52 Week High
- THFF $54.63
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- THFF 64.58
- PHAR 51.11
- Support Level
- THFF $51.91
- PHAR $10.23
- Resistance Level
- THFF $54.63
- PHAR $11.21
- Average True Range (ATR)
- THFF 1.18
- PHAR 0.27
- MACD
- THFF 0.23
- PHAR -0.14
- Stochastic Oscillator
- THFF 91.04
- PHAR 34.01
About THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.